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ABSTRACT
The human respiratory syncytial virus (HRSV) core viral RNA polymerase comprises the large polymerase protein (L) and its
cofactor, the phosphoprotein (P), which associate with the viral ribonucleoprotein complex to replicate the genome and, to-
gether with theM2-1 protein, transcribe viral mRNAs.While cellular proteins have long been proposed to be involved in the
synthesis of HRSV RNA by associating with the polymerase complex, their characterization has been hindered by the difficulty
of purifying the viral polymerase frommammalian cell culture. In this study, enhanced green fluorescent protein (EGFP)-tagged
L- and P-protein expression was coupled with high-affinity anti-GFP antibody-based immunoprecipitation and quantitative
proteomics to identify cellular proteins that interacted with either the L- or the P-proteins when expressed as part of a biologi-
cally active viral RNP. Several core groups of cellular proteins were identified that interacted with each viral protein including, in
both cases, protein chaperones. Ablation of chaperone activity by using small-molecule inhibitors confirmed previously re-
ported studies which suggested that this class of proteins acted as positive viral factors. Inhibition of HSP90 chaperone function
in the current study showed that HSP90 is critical for L-protein function and stability, whether in the presence or absence of the
P-protein. Inhibition studies suggested that HSP70 also disrupts virus biology andmight help the polymerase remodel the nu-
cleocapsid to allow RNA synthesis to occur efficiently. This indicated a proviral role for protein chaperones in HRSV replication
and demonstrates that the function of cellular proteins can be targeted as potential therapeutics to disrupt virus replication.
IMPORTANCE
Human respiratory syncytial virus (HRSV) represents a major health care and economic burden, being the main cause of severe
respiratory infections in infants worldwide. No vaccine or effective therapy is available. This study focused on identifying those
cellular proteins that potentially interact specifically with the viral proteins that are central to virus replication and transcrip-
tion, with a view to providing potential targets for the development of a specific, transient therapeutic which disrupts virus biol-
ogy but prevents the emergence of resistance, while maintaining cell viability. In particular, protein chaperones (heat shock pro-
teins 70 and 90), which aid protein folding and function, were identified. The mechanism by which these chaperones contribute
to virus biology was tested, and this study demonstrates to the field that cellular protein chaperones may be required for main-
taining the correct folding and therefore functionality of specific proteins within the virus replication complex.
Human respiratory syncytial virus (HRSV) is the leading causeof severe respiratory tract infections in newborn children
worldwide (1). It infects almost all infants within the first 2 years
of life and is themain cause of infant bronchiolitis. Currently, only
ribavirin is approved for therapeutic treatment, and there is a
pressing need for additional therapies to be developed (2, 3).
HRSV belongs to the genus Pneumovirus of the family Paramyxo-
viridae and the orderMononegavirales (1). The viral genome con-
sists of a nonsegmented, approximately 15-kb RNA of negative
polarity that encodes 11 proteins. As with all the members of the
Mononegavirales, the genomic RNA of HRSV is associated with
the viral nucleoprotein (N) and maintained as a helical N-RNA
ribonucleoprotein (RNP) complex (4). The RNP is used as a tem-
plate for transcription and replication by the RNA-dependent
RNA polymerase (RdRp) complex, which consists of the large
polymerase protein (L) and its cofactor, phosphoprotein (P).
Whereas N-, P-, and L-proteins are sufficient to mediate viral
genome replication, transcription activity also requires the M2-1
protein, which functions as a polymerase cofactor (5). The specific
recognition of the viral N-RNA complex by the RdRp constitutes
a prerequisite for viral transcription and replication. This recog-
nition is mediated by the P-protein (6), which interacts with the
L-, N-, and M2-1-proteins. A feature of the Mononegavirales is
that theRdRp is present in the virus particle to initiate viralmRNA
transcription upon release of the RNP in the cytoplasm.
Cellular proteins have been shown to play crucial roles in viral
RNA synthesis for a number of other viruses that encode RdRps.
These roles include involvement in the formation of virus facto-
ries (7, 8) and acting directly as cofactors to regulate RdRp activity
(9, 10). Several cellular proteins have been shown to potentially
associate with the HRSV L-, P-, N-, andM2-1-proteins, including
heat shock proteins (HSPs). Expression and purification of the












L-protein (with the P-protein) from insect cells previously sug-
gested an association with HSP70 (11), and data from coimmu-
noprecipitation studies suggested that HSP70 associates with the
P-protein alone (12). The association of the polymerase complex
with HSP70 was also observed within lipid raft membranes in
virus-infected cells (13). HSP90 has been identified within the
virion proteome (14), and ablation of the HSP90 chaperone func-
tion inHRSV-infected cells resulted in a decrease in progeny virus
(14, 15). Geller et al. postulated that HSP90 contributed to L-pro-
tein stability (15), an effect which had been shown previously for
vesicular stomatitis virus (VSV) (16), another member of the
Mononegavirales. Further, Geller et al. and Radhakrishnan et al.
demonstrated potential antiviral activities of HSP90 inhibitors on
HRSV biology (14, 15), and these were refractive to resistance (15).
A particular difficulty in studying the HRSV polymerase com-
plex is the lack of immunological reagents to the L-protein to
couple with immunoprecipitation (IP) strategies. L expression in
eukaryotic cell culture systems also seems to require coexpression
of the P-protein (11, 17). To overcome these difficulties, and to
map which cellular proteins associate with the HRSV polymerase
complex in mammalian cells, we made use of a plasmid-based
HRSV rescue system in which enhanced green fluorescent protein
(EGFP) is inserted either between domains V and VI of the L-pro-
tein (EGFP-L) (17) or within the disordered N-terminal region of
the P-protein (EGFP-P). These fusion proteins maintain biologi-
cal activity in the context of reconstituted RNPs (a “minireplicon”
system) and are able to both replicate and transcribe viral RNA
when the N- and M2-1-proteins are expressed from additional
support plasmids (17). The activity of the replicon can be moni-
tored via the expression of a reporter protein, such as luciferase.
The EGFP moiety allows the use of a highly specific, single-chain
antibody to EGFP to facilitate detection or purification of either
the EGFP-L or the EGFP-P protein in the context of the minirep-
licon system. GFP-Trap technology was coupled with label-free
quantitative proteomics for the identification and discrimination
of specific interacting proteins. Previous studies investigating the
interactomes of HRSV NS1 and NS2, porcine reproductive and
respiratory syndrome (PRRSV) and infectious bronchitis virus
(IBV) N-proteins and Zaire ebolavirus (EBOV) VP24, have also
used this approach (18–21). Similar to the study investigating
EBOV VP24, small-molecule inhibitors were subsequently ap-
plied to decipher the potential role(s) of identified binding part-
ners in the context of wild-type (WT)_infection and other assays.
Our data indicated that the EGFP-L and EGFP-P proteins as-
sociate with a number of cellular proteins, including chaperones.
Ablation of the function of these proteins had a detrimental effect
on virus biology. Specifically, the protein chaperone function of
HSP90 was required to maintain the stability of the L-protein,
both in association with the P-protein and in isolation, and it was
determined that HSP70 plays a positive role in HRSV RNA syn-
thesis. This adds to the body of evidence that the functions of
cellular proteins is critical for virus biology and suggests that these
functions can be targeted for the development of antiviral thera-
pies (15, 22, 23).
MATERIALS AND METHODS
Cells and virus. HEp2 and A549 cells were obtained from the Public
Health England Culture Collection and were grown at 37°C with 5%CO2
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% (vol/vol) fetal bovine serum (FBS) and 1% (vol/vol) penicillin-strep-
tomycin. For transfection experiments using EGFP-L (see below), BSRT7
cells (baby hamster kidney [BHK] cells expressing T7 RNA polymerase
[12]; maintained by the addition of G418) were grown in DMEM supple-
mented with 1 Glutamax (Invitrogen) and 10% (vol/vol) FBS. HRSV
strain A2 was propagated in HEp2 cells and concentrated by using a su-
crose gradient-based method which also removes cellular contaminants
(24). Virus was concentrated in the 30% phase of a discontinuous sucrose
gradient and stored in this fraction for stability during long-term storage.
Virus titers were calculated as previously described (25). HRSV strain A2
for experiments related to in vitro RNA synthesis was also propagated in
HEp2 cells but was not sucrose purified.
pP-EGFP plasmid construction. A unique BamHI site was intro-
duced at nucleotide 96 of the P gene in the pP plasmid by site-directed
mutagenesis using the QuikChange kit (Stratagene). The EGFP gene was
then inserted in framewith the P open reading frame (ORF) at the BamHI
site.
EGFP-L and EGFP-P IPs. For IPs, BSRT7 cells were routinely seeded
in two 10-cm2 dishes per condition and were 90% confluent prior to
transfection. Cell monolayers were cotransfected with 12.5 g of MiniG-
Luc (which carries the genes for the HRSV minigenome, including the
firefly luciferase reporter gene), 12.5g of pN, 12.5g of pP or pP-EGFP,
6.25g of pL or pL-EGFP, and 12.5g of pM2-1 plasmids and using 50l
of Lipofectamine 2000 (Invitrogen) according to the manufacturer’s in-
structions. Cells were harvested 24 h posttransfection, and cell lysate was
incubated with GFP-Trap beads (Chromotek) for 2 h. The bead pellet was
washed and suspended in 50 l of glycine elution buffer (0.2 M glycine,
pH 2.5). The supernatant was neutralized with 5 l of 1 M Tris base (pH
10.4) in preparation for liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS).
IP sample preparation for proteomics. Protein content and volume
were normalizedwith 25mMammoniumbicarbonate. Rapigest (Waters)
was added to the samples prior to heating at 80°C for 10 min. Samples
were then reduced with 3 mM dithiothreitol (DTT; Sigma) at 60°C for 10
min and alkylatedwith 9mM iodoacetimde (Sigma) at room temperature
for 30 min in the dark. Proteomic-grade trypsin (Sigma) was added at a
protein:trypsin ratio of 50:1, and samples were incubated at 37°C over-
night. Rapigest was removed by adding trifluoroacetic acid (TFA) to a
final concentration of 1% (vol/vol) and incubating at 37°C for 2 h. Peptide
samples were centrifuged at 12,000 g for 60 min (4°C) to remove pre-
cipitated Rapigest. Peptides were concentrated and desalted using C18
Stage tips (Thermo Scientific), then dried using a centrifugal vacuum
concentrator (Jouan) and resuspended in a 0.1% (vol/vol) TFA, 3% (vol/
vol) acetonitrile solution.
Nano-LCESI-MS/MS analysis.Peptidemixtures (2l) were analyzed
by online nanoflow liquid chromatography (nano-LC) by using the nano-
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ACQUITY-nLC system (Waters MS Technologies, Manchester, United
Kingdom) coupled to an LTQ-Orbitrap Velos mass spectrometer (Ther-
moFisher Scientific, Bremen, Germany) equipped with the manufactur-
er’s nano-electrospray ionization (ESI) ion source. The analytical column
(nanoACQUITY ultraperformace LC BEH130 C18, 15-cm by 75-m by
1.7-m capillary column) was maintained at 35°C with a flow rate of 300
nl/min. The gradient consisted of 3 to 40% acetonitrile in 0.1% formic
acid for 90 min and then a ramp of 40 to 85% acetonitrile in 0.1% formic
acid for 3 min. Full-scan MS spectra (m/z range, 300 to 2,000) were ac-
quired by the Orbitrap at a resolution of 30,000. Analysis was performed
in data-dependentmode. The top 20most intense ions from theMS1 scan
(full MS) were selected for tandem MS by collision-induced dissociation
(CID), and all product spectra were acquired in the LTQ ion trap.
Thermo RAW files were imported into Progenesis LC-MS (version
4.1; Nonlinear Dynamics). Runs were time aligned using default settings
and an autoselected run as the reference. Peaks were picked by the soft-
ware and filtered to include only a charge state of between 2 and 6.
Peptide intensities were normalized against the reference run, and these
intensities were used to highlight differences in protein expression be-
tween control and treated samples with supporting statistical analysis
(analysis of variance P values) calculated by the Progenesis LC-MS soft-
ware. Spectral data were transformed to .mgf files with the Progenesis
LC-MS program and exported for peptide identification using theMascot
search engine (version 2.3.02; Matrix Science). Tandem MS data were
searched against the Mus musculus, Cricetulus griseus, and human respi-
ratory syncytial virus A (strain A2) predicted proteomes (Uniprot release
2013_04). Mascot search parameters were as described above. Results
were imported into the Progenesis LC-MS program as .xml files.
HSP90 inhibition studies. For A549 and BSRT7 cells, the chaperone
activity of HSP90 was initially inhibited by applying 0.0625 to 5 M con-
centrations of the geldanamycin derivative 17-AAG (Calbiochem) diluted
in dimethyl sulfoxide (DMSO; vehicle control). Cell viability/cytotoxicity
were assessed using a colorimetric MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] assay. Cells were seeded at a density of
3.8 103 cells/well (for 40 to 50% confluence), 1 104 cells/well (for 60
to 70% confluence), or 1.5 104 cells/well (for 80 to 90% confluence) in
clear 96-well microplates 24 h prior to 17-AAG treatment. Following 17-
AAG treatment,MTTpowder (Sigma)was dissolved inDMEM(plus 10%
[vol/vol] FBS) at 37°C to make a 10 mM solution and filtered through a
0.2-m filter. Medium was aspirated, and the wells were washed with
phosphate-buffered saline (PBS). FilteredMTT (100l/well) was applied,
and the plates were incubated for 45 min at 37°C. MTT was removed and
replaced with 100l/well DMSO, and cultures were thoroughly mixed by
pipetting until MTT (a yellow tetrazole) was reduced to purple formazan
in living cells. Absorbance was thenmeasured at wavelengths between 425
and 570 nm on a Dynex plate reader. A dose-response curve was then
produced to assess cell viability (data not shown). A more precise 50%
effective concentration (EC50) could then be established alongside immu-
noblot analysis results with 17-AAG-treated cells to establish a suitable
time course (18, 24, and 40 h posttreatment) for both cell lines.
HRSV-infected cells (multiplicity of infetion [MOI], 3) and mock-
infected cells were routinely treated with 0.5 M 17-AAG 4 h postinfec-
tion (p.i.) in comparison to nontreated and vehicle control-treated cells.
For minireplicon experiments, BSRT7 cells were transfected 4 h prior to
treatment with 0.5M17-AAG. RNA (for quantitative PCR [qPCR]) and
cell pellets (forwhole-cell lysis)were processed 22 hpost-virus application
or minireplicon transfection and 18 h post-17-AAG treatment. To assess
17-AAG activity, cell pellets were lysed in RIPA buffer (50 mM Tris [pH
7.5], 150 mM NaCl, 1% [vol/vol] NP-40 alternative, 0.5% [wt/vol] so-
dium deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) supplemented
with 1 EDTA-free Complete protease inhibitor mixture (Roche Applied
Science) per 50 ml buffer and immunoblotted with an antibody to Cdc2
(A17; Abcam), a knownHSP90 client protein, whichwas used as amarker
of proteasome-mediated Cdc2 degradation.
HSP70 inhibition studies. MTT assays (data not shown) were again
used to establish an EC50 prior to the application of small-molecule in-
hibitors VER-155008 (VER; SML0271), Pifithrin- (PIF; P0122), MKT-
077 (M5449; Sigma-Aldrich), and YM-1 (500615;MerckMillipore) in the
context of HRSV infection (A549 cells) or the minireplicon (BSRT7 cells)
(data not shown). HSP70 inhibitors were applied to infected A549 cells or
transfected BSRT7 cells as described above.
Cell extract in vitro RNA synthesis assay for HSP70 function. Anal-
ysis of HRSV transcription in crude cell extracts was based on a protocol
published previously for vesicular stomatitis virus (26). HEp2 cells in
six-well plates were infected ormock infected with RSV at anMOI of 5 for
17 h, following which the medium was replaced with medium containing
2g/ml actinomycin D. After 1 h, cells were washed with PBS and treated
with 250 g/ml lysolecithin in PBS for 1 min on ice. The lysolecithin/PBS
mix was aspirated, and cells from each well were scraped into 62 l of
transcription buffer (2g/ml actinomycin D, 50mMTris-acetate [pH 8],
8 mMMg-acetate, 300 mM K-acetate, 2 mMDTT, 1 mM spermidine, 10
mMcreatine phosphate, 1g/ml aprotinin, 16U creatine phosphokinase,
50 M ATP, 1 mM CTP, and either 50 M or 1 mM GTP or UTP,
depending on the radiolabeled NTP used). Samples were centrifuged at
800 g for 5 min, and the supernatant was collected. Aliquots (25 l) of
the cell extract were combined with additional transcription buffer con-
taining 10 Ci [-32P]GTP or [-32P]UTP. RNase inhibitor and either
DMSO or VER diluted in DMSO were added to a total reaction mixture
volume of 50 l. Reaction mixtures were incubated for 4 h at 30°C, fol-
lowing which total RNAwas extracted using a Qiagen RNeasy kit, accord-
ing to the manufacturer’s instructions. Purified total RNA samples were
further processed by RNase H digestion, to remove poly(A) tails from
mRNA transcripts, thus allowing resolution of individual mRNA bands.
Total RNA was incubated for 1 h at 30°C in 50 mM Tris-Cl (pH 7.5), 10
mMMgCl2, 1 mMEDTA, 10mMDTT, 10% glycerol, 200 ng oligo(dT)15
and 2.5 U RNase H (NEB) in a total volume of 30 l. Total and RNase
H-treated RNA samples were subjected to denaturing gel electrophoresis
on a 4% acrylamide gel containing 7 M urea and analyzed by autoradiog-
raphy. The RNA signal was quantified by analyzing TIF images of the
autoradiograms by using Quantity One software. To ensure that the val-
ues obtained were in the linear range, a standard curve was generated by
preparing a 2-fold dilution series of amolecular weightmarker. This stan-
dard was included on all scans.
Minimalist in vitro RNA synthesis assay using purified HRSV poly-
merase. The HRSV L/P/HSP70 complex was purified from insect cells as
described previously (11). An RNA oligonucleotide (Dharmacon) repre-
senting nucleotides 1 to 25 of the trc promoter sequence (2 M) was
combinedwith transcription buffer containing 50mMTris-HCl (pH7.4),
8 mMMgCl2, 5 mM DTT, 10% glycerol, and 250 MGTP, 50 MATP,
50 M CTP, and 50 M UTP, with 10 Ci of [-32P]GTP and either
DMSOor various concentrations of VER (diluted inDMSO) as indicated.
Reaction mixtures were incubated at 30°C for 10 min, and then HRSV
L/P/HSP70 (containing200ng of L-protein)was added to the transcrip-
tionmix, such that the final reaction volumewas 50l. Reactionmixtures
were incubated for 3 h at 30°C, then heated to 90°C for 3min to inactivate
the RdRp and cooled briefly on ice. The RNAwas analyzed by electropho-
resis on a 20% polyacrylamide gel containing 7 M urea in Tris-borate-
EDTA buffer. Themolecular weight ladder was generated by alkali hydro-
lysis of a 32P-end-labeled RNA oligonucleotide representing the
anticipated RNA products. RNA products were visualized and quantified
by phosphorimage scanning and Quantity One software.
Immunofluorescence confocal microscopy. Coverslip-adhered cell
monolayerswere fixedwith paraformaldehyde,made permeablewith PBS
containing 0.1% (vol/vol) Triton, and probed with anti-HSP90 antibody
(4F10; sc-69703; Santa Cruz Biotechnology) diluted 1:50 in PBS contain-
ing 2% FBS. The primary antibody was detected using an Alexa Fluor-
conjugated secondary antibody (A4116) diluted 1:200 in PBS containing
2% FBS, prior to mounting with Prolong Gold antifade reagent (Invitro-
gen). Confocal microscopy images were captured on an LSM510 META
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microscope (Carl Zeiss Ltd.) equipped with 40 and 63, 1.4-numerical
aperture, oil immersion lenses. Pinholes were set to allow optical sections
of 1 to 2mtobe acquired.Where possible, all fluorescencewasmeasured
in the linear range.
Immunoblot analysis. Soluble cellular proteins were obtained as de-
tailed above, and total protein concentrations were determined via the
bicinchoninic acid assay (Pierce). Proteins (5 to 7.5 g) were resolved by
7.5 or 10%SDS-PAGE and transferred to polyvinylidene difluoridemem-
branes (Millipore), using a Bio-Rad semidry transfer apparatus, and the
following antibodies were applied: CDC2 (A17; Ab18), HSP90 (S88;
Ab1429), HRSV (polyclonal to detect structural proteins; ab20745) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 6C5; Ab8245) (all
antibodies were obtained from Abcam). HSP90 (4F10; sc-69703), Lucif-
erase (251-150; sc-32896), and STI1 (28; sc-136082) were obtained from
Santa Cruz Biotechnology. The following horseradish peroxidase-conju-
gated secondary antibodies were detected with enhanced chemilumines-
cence: anti-rabbit (Ab6154) and anti-mouse (A4116) antibodies were ob-
tained from Sigma, and anti-goat antibody (Ab6741) was obtained from
Abcam.
Quantitative real-time PCR. To measure mRNA levels, cDNA was
synthesized from 1 g of total RNA using the ThermoScript reverse tran-
scription-PCR (RT-PCR) system (Invitrogen) according to the manufac-
turer’s instructions. Twenty microliters of cDNA product was then di-
luted with 80 l of nuclease-free water. For each qPCR mixture, 1 l of
diluted cDNA and 1 l of a primer pair (0.5 l of each of the forward
primer and reverse primer) were mixed with 10l of SYBR greenmaster-
mix (Bio-Rad) to make up a final reaction volume of 20l with nuclease-
free water. qPCR was performed on a DNA Engine Opticon 2 system
(Bio-Rad), following the recommended protocol. The results of three
independent experiments were averaged and normalized by using either a
murine or a human GAPDH gene control, depending on the experiment.
Luciferase assay. BSRT7 cells were routinely transfected with the
complete (L) luciferase-based or incomplete (L) luciferase-based
HRSV minireplicon reporter plasmid system 4 h prior to drug treatment
and lysed in an appropriate amount of passive lysis buffer (Promega) for
15 min at room temperature 22 h posttransfection. Lysate (20 l) was
pipetted into a 96-well white flat-bottom plate and assayed using the dual
luciferase system (Promega) according to the manufacturer’s instruc-
tions. The luminescent signal was recorded using a luminescence reader
(BMG Labtech). The results of three independent experiments were aver-
aged, with normalization to theRenilla control. Luciferase expression was
expressed in relative light units (RLU), relative to a no-drug control (0l).
Pulse-chase labeling. Cells were prepared for pulse-chase 22 h post-
transfection with EGFP plasmids; all steps of the pulse-chase were per-
formed in the presence or absence of 1M17-AAG.Cells were depleted of
methionine by incubation in methionine-free medium (Gibco) for 2 h.
Cells were then pulse-labeled with [35S]methionine (PerkinElmer) for 30
min and either harvested immediately or chased withmedium containing
an excess of cold methionine (50 mM) for 2 h at 37°C. GFP-tagged pro-
teins were isolated from the cell lysates by using GFP-Trap beads (Chro-
motek), and proteins were analyzed by SDS-PAGE and autoradiography.
A plasmid carrying the EGFP-ADAR1 genes was the kind gift of M.
Carmo-Fonseca (27) and was used as a control.
Flow cytometry. Flow cytometric analysis of GFP-positive cells was
performed on a FACSCalibur apparatus and using CellQuest software
(BD Biosciences). Data analysis was performed using FlowJo (version
X.0.7; Tree Star Inc.). Live cells were defined based on forward and side
scatter. Cells in the live gate were then plotted against side scatter and FL1
for GFP expression, and the mean percentage of GFP-positive cells was
obtained for each condition.
RESULTS
Identification of potential interacting partners of the HRSV
polymerase complex. To obtain a more complete picture of the
potential interaction partners of the HRSV polymerase complex,
IP coupled with quantitative proteomics was used to identify cel-
lular proteins that associated with the L- and P-proteins. This
system utilized the expression of either a biologically active L-
EGFP or P-EGFP in the context of anHRSVminireplicon harbor-
ing the luciferase gene, together with the appropriate wild-type
proteins (N, M2-1, P [if EGFP-L] and L [if EGFP-P]) expressed
from support plasmids in BSRT7 cells (17). Replication of the
minireplicon RNA was dependent on the presence of functional
L- (or EGFP-L), P- (or EGFP-P), andN-proteins. Transcription of
luciferasemRNA from theminigenomewas enhanced in the pres-
ence of M2-1 (17, 28), allowing replicon activity to be monitored
bymeasuring the amount of the reporter gene mRNA, protein, or
activity.
A highly specific GFP-Trap was used to selectively precipitate
the EGFP-L or EGFP-P fusion protein and its interacting partners,
as described previously (18–20). To identify bound proteins, la-
bel-free quantitative proteomics was used to compare the abun-
dance of immunoprecipitated peptides from this system with the
abundance of those precipitated from a control sample, in which
cells were transfected with the same minireplicon system except
that a wild-type, untagged L- or P-protein was used. This control
was used to identify cellular proteins that bound to the monova-
lent agarose GFP-Trap beads only. LC-MS/MS analysis of the IP
proteins was conducted on material eluted in 0.2 M glycine, pH
2.5.
To provide a statistically robust data set, both EGFP-L and -P
and the untagged control were purified independently in tripli-
cate, and each eluted sample was further analyzed in triplicate by
LC-MS/MS. Progenesis software was used to analyze the LC-
MS/MS data against mouse and hamster databases to derive a list
of cellular proteins that potentially bound to EGFP-L or EGFP-P.
The results from the mouse database were used, as they provided
higher coverage and subsequent protein identification than the
hamster database. Viral proteins were identified directly from
peptide assignment to a FASTA file listing the amino acid se-
quences of the L-, P-, N-, and M2-1-proteins.
LC-MS/MS analysis identified 337 cellular proteins that copu-
rified with EGFP-L. To identify likely specific interactions over
background/random interactions, these proteins were triaged
based on several different criteria. First, proteins identified and
quantified by a single peptide were removed, as single-peptide
identification in many cases does not provide robust identifica-
tion. The identification of a protein was based on use of unique
peptides (e.g., some proteins can share the same peptide sequence,
and in such cases the sequence was not used). Second, the false-
discovery rate (FDR) was set at 1% or below, implying that theo-
retically 99 out of 100 proteins would be identified correctly.
Third, using the quantitative aspect to compare replicate control
and experimental samples, both the binding ratio and statistical
significance could be assigned to potential interacting partners.
The binding ratio refers to the relative quantification when com-
paring the tagged replicon system to the untagged control and is
expressed as the fold change.
Proteins interacting specifically with the bait would be ex-
pected to be enriched to a greater extent than in the control and
show a correspondingly high binding ratio. Proteins binding to
the beads equally in both control and test samples (i.e., nonspe-
cific binders) will have a binding ratio near 1.0. These can include
common, low-order “hits,” such as vimentin, nucleolin, cytoskel-
etal, and ribosomal proteins, certain classes of helicases, and heat
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shock proteins, which associate with the binding matrix (29).
Low-order hits with a binding ratio of 1.9 or less were therefore
removed. Fourth, the data sets were further processed by compar-
ison to previously determined EGFP and matrix interactomes to
filter out likely false positives (18–20, 29, 30).
Using these criteria, 19 cellular proteins were found to interact
with the EGFP-L protein (see Table S1 in the supplemental mate-
rial). LC-MS/MS analysis also identified the EGFP-L, -P, and -N
proteins from the EGFP-L and EGFP-P IPs, indicating that confi-
dence could be placed in the approach, as these proteins form
known interactions (31). TheM2-1 proteinwas detected (data not
shown) but was only identified by a single peptide and was there-
fore excluded from the data presented inTable S1. The PANTHER
bioinformatic algorithm was applied to the data set in Table S1
(excluding viral proteins) to identify groups of polypeptides that
had potentially common functionality. The output indicated that
a number of the EGFP-L-interacting proteins with ratios greater
than 2.0 clustered on proteins with folding/chaperone activities
and membrane trafficking, nucleic acid binding, and transferase
activities. When the data were analyzed as a volcano (scatter) plot
of significance versus binding ratio, it was clear that proteins in-
volved in chaperone function formed a major part of the EGFP-L
interactome (Fig. 1).
In our experience, and that of others, there is good agreement
between using quantitative proteomics to identify interacting
partners from IP-based experiments and subsequent follow-on
experiments using specific analysis techniques (18–20, 32, 33).
Aspects of the EGFP-L interactome were validated by conducting
repeat IPs of control and experimental systems. Specific virus and
cellular proteins were subsequently probed by immunoblot anal-
ysis (Fig. 2). Biological activity of theHRSVRNPswas validated by
probing for luciferase, which was expected to be expressed from
theminireplicon in the presence of functional support proteins: L,
N, P, and M2-1 for the control system and EGFP-L, N, P, and
M2-1 for the experimental system. There was less luciferase ob-
served in the experimental system (Fig. 2, top panel), in agreement
with previously published work indicating that the insertion of
EGFP into the HRSV L-protein attenuates but does not abolish
activity (17). No luciferase was detected in the bound fraction
(Fig. 2). The expression of N, P, andM2-1 from the support plas-
mids was confirmed in the input samples for both the control and
experimental systems. However, no viral proteins were precipi-
tated in the sample lacking an EGFP tag, and only the N- and
P-proteins could be detected in the bound fraction of the EGFP-L
sample (Fig. 2, middle panel). M2-1 was not detected by immu-
noblotting in the bound fraction from either the control or exper-
imental system (Fig. 2); this is consistent with previous reports
(34) in which M2-1 probably binds to RNA rather than a direct
interaction with the P-protein. In the bound fraction for L-EGFP,
the immunoblot analysis, though not quantitative, indicated that
more N was being captured than P andM2-1. This was consistent
with the quantitative LC-MS/MS analysis that indicated that N
had a higher binding ratio than P (19.9 and 4.0, respectively) (see
Table S1 in the supplemental material). This was indicative that
RNP complexes may have been precipitated.
To validate potential cellular interactors identified by LC-MS/
MS, we probed the IP samples using immunoblot analysis: stress-
induced phosphoprotein 1 (STIP1; ratio, 15.5) and HSP90 (ratio,
8.5) were precipitated in greater quantities from the experimental
FIG 1 Analysis via label-free LC-MS/MS of cellular proteins that associated
with the EGFP-L protein in the context of the HRSV minireplicon. Control
and experimental samples (performed in triplicate) were each processed in
triplicate by LC-MS/MS. Statistical analysis using a volcano plot identified
proteins of interest, which are displayed both as large-magnitude ratio changes
(x axis) as well as high statistical significance (y axis; log10 of the P value).
Dashed red lines show chosen cutoff ratios of change:2 (log 2	 1) and P

0.05 [log(100.05) 	 1.3]. Points highlighted in black or green had a ratio
change of more than 2, in comparison with those shown in gray; green high-
lights proteins with a chaperone or chaperone-associated function. FIG 2 Expression of luciferase from the control and experimental minirepli-
con system was confirmed via immunoblotting with a probe for an antilu-
ciferase antibody. Luciferase was below the limit of detection in the immuno-
precipitated (bound) fraction, as expected. Expression of the N-, P-, and
M2-1-proteins was confirmed via immunoblotting with a probe for a poly-
clonal anti-RSV antibody, for both the control and experimental system. Only
the N- and P-proteins could be detected in the bound fraction from the exper-
imental system and were not found in the bound fraction from the control
system. The presence of the cellular proteins HSP90 and STIP1 was also inves-
tigated in the IPs by immunoblotting.
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system than the control precipitation, again in agreement with the
proteomics screen (Fig. 2, lower panels). HSP90was also observed
in the bound fraction from the control experiment to a lesser
extent, and this was in line with previous observations that chap-
erone proteins associate with the bindingmatrix in an IP (29), but
in the absence of a specific interaction, they generally have a bind-
ing ratio of 1.0 or less.
Themini-replicon system required the stable expression of the
L-protein together with theN-, P-, andM2-1-proteins to generate
a functional RNP thatmimicked those found in infected cells (17).
Thus, binding data from the EGFP-L IP could reflect a mixture of
cellular proteins that bound to the L-protein and/or to the other
viral components. To explore this, and also to investigate whether
cellular proteins could interact directly with the polymerase cofac-
tor P-protein, we engineered a biologically active P-EGFP protein.
Sequence alignment between HRSV P and pneumovirus of mice
(PVM) P-proteins revealed a region of low sequence conservation
located in the N-terminal region of P (data not shown), which is a
naturally disordered region. Insertion of EGFP at residue K32 of
the HRSV P-protein resulted in an EGFP-P fusion protein that
still localized to inclusion bodies (IBs) and retained 10% of activ-
ity compared to WT P, as assayed using a minireplicon system
(data not shown). Accordingly, P-EGFPwas used as bait in further
IPs, in the context of reconstituted minigenome RNPs. LC-
MS/MS analysis of the EGFP-P IP identified both N and L (see
Table S2 in the supplemental material), thus confirming known
interactions.M2-1was also identified, but again, onlywith a single
peptide and was therefore excluded from Table S2. Thirty-nine
cellular proteins with a binding ratio of 2 or more and identified
by two ormore peptides had the potential to interact with P-EGFP
(see Table S2). As with the EGFP-L IP, cellular polypeptides in-
volved in chaperone function were prominent, including STIP1,
DNAJA2, and HSP90.
HRSV macromolecular synthesis requires cellular chaper-
one activity. Previous studies have indicated that HRSV titers de-
creases or that virion assembly and transmission are impaired in
infected cells when they are treated with 17-AAG (14) or other
HSP90 inhibitors, depending on the time point of inhibitor appli-
cation (14, 15), suggesting a key role for HSP90 in the life cycle of
the virus. In the current study, an assay point of 4 h p.i. for inhib-
itor application and 22 h p.i. were chosen to assess effects on virus
biology. This was based on a one-step growth curve analysis of the
A2 strain in A549 cells with an MOI of 3, allowing us to delineate
a time point after the release of progeny virus from the first round
of infection but before the onset of release of virus from reinfec-
tion (data not shown). The quantitative interactome analysis in-
dicated that HSP90 had a higher binding ratio with the L- than the
P-protein (8.5- versus 2.9-fold over the control, respectively) (see
Tables S1 and S2 in the supplemental material) and thus may be
involved directly in L-protein function. To investigatewhether the
decrease in viral titer observed in the presence of 17-AAGwas due
to a reduction in viral mRNA synthesis and/or viral protein abun-
dance, we assessed the effect of titrating 17-AAG on HRSV-in-
fected cells in comparison to untreated and vehicle control
(DMSO)-treated cells. The inhibitor was applied 4 h p.i., and a
concentration range was used that maintained cell viability (data
not shown). The activity of the inhibitor was confirmed at higher
doses by the depletion of Cdc2 (Fig. 3A), a protein whose abun-
dance is dependent on HSP90 chaperone activity (13). Con-
versely, at the concentrations tested, there was no significant effect
on the abundance of HSP90 (Fig. 3A). However, as the concentra-
tion of 17-AAG increased, there was a marked dose-dependent
decrease in the abundance of viral proteins (Fig. 3A). This was
mirrored by a corresponding decrease in all viral mRNA species in
HRSV-infected cells treated with 17-AAG (at 0.5M, applied at 4
h p.i.), as determined by qRT-PCR (Fig. 3B). This was similar to
the observations that treatment of infected cells with 17-AAG has
a detrimental effect on HRSV biology (14, 15).
The ablation of viral gene expression in infected cells treated
with 17-AAGmay have been due to an overall decrease in stability
of all viral proteins or, specifically, one or more of the proteins
involved in RNA synthesis (e.g., the L-, P-, N-, and M2-1-pro-
teins). The work of Geller et al. (15) suggested the latter was the
most likely possibility, given that the L-protein could not be de-
finitively identified. To investigate this further, wemade use of the
minireplicon system in which the wild-type L-, P-, N-, andM2-1-
proteins were provided from support plasmids, and hence their
FIG 3 (A) Immunoblot analysis of mock-infected and HRSV-infected A549
cells that were treated with 17-AAG from 4 h p.i. in comparison to a vehicle
control (DMSO) anduntreated cells. Viral proteins visually decreased in abun-
dance with increased 17-AAG concentration. Cdc2, an HSP90 client protein,
was used as amarker of inhibitor activity. The abundance ofHSP90was shown
to be unchanged in nontreated, vehicle control-treated, and 17-AAG-treated
cells and was also used as a loading control. (B) The mRNA level of each viral
transcript was compared by qRT-PCR at 22 h p.i. in the presence or absence of
0.5 M 17-AAG, which was added at 4 h p.i. The data were normalized to the
control gene GAPDH and are shown as the fold change for each mRNA be-
tween 17-AAG-treated HRSV-infected cells andmock-treated HRSV-infected
cells.
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synthesis was not dependent on any viral processes. In this system,
HRSV-driven luciferase expression showed a dose-dependent in-
hibition by the addition of 17-AAG (Fig. 4A). The EC50 was ap-
proximately 0.2 M, similar to that seen for authentic viral gene
expression (Fig. 3). When polypeptide expression was detected by
immunoblot analysis, luciferase was readily detected in the ab-
sence, but not the presence of 17-AAG (Fig. 4B), consistent with
the activity assays (Fig. 4A). Likewise, qRT-PCR revealed an ap-
proximately 5-fold decrease in the amount of luciferase mRNA in
replicon-expressing cells treated with 0.5 M 17-AAG compared
to the amount of luciferase mRNA in replicon-expressing cells in
the absence of 17-AAG (Fig. 4C). However, immunoblot analysis
indicated that the levels of P, N, and M2-1 expressed from the
support plasmids were unchanged in the absence or presence of
17-AAG (Fig. 4B). The L-protein could not be detected due to the
lack of a specific antibody. Thus, 17-AAG inhibits the process of
viral gene expression but not by destabilizing all virus polypep-
tides.
HSP90 chaperone activity supportsHRSV replicationby sta-
bilizing the L-protein. In the context of the minireplicon system,
17-AAG treatment 4 h posttransfection inhibited viral mRNA
synthesis but did not affect the accumulation of the P-, N-, and
M2-1-proteins expressed from support plasmids (Fig. 4B). How-
ever, the anti-HRSV polyclonal antibody used did not detect the
L-protein in this system. To determine if 17-AAG directly affected
L-protein abundance, we used the GFP moiety of the EGFP-L
protein as a detection tag. Confocal microscopy was used to de-
termine the intracellular localization of the L-protein in the con-
text of theminireplicon systemwith and without 0.5M17-AAG
(Fig. 5A). In the absence of 17-AAG, the EGFP-L could be readily
detected, showing a punctate cytoplasmic distribution reminis-
cent of the cytoplasmic IBs as previously observed either in in-
fected cells or cells cotransfected with N- and P-proteins (17).
Furthermore, the EGFP-L puncta strongly colocalized with
HSP90. In contrast, no EGFP-L fluorescence could be detected in
transfected cells that had been treated with 17-AAG, suggesting its
destabilization (Fig. 5A). To quantify the percentage of cells that
were positive for EGFP-L expression, in the presence and absence
of 17-AAG, transfected cells were analyzed by flow cytometry. In
the absence of drug, around 10%of the transfected cell population
was positive for L-EGFP expression, either when expressed alone
or with the P-protein (Fig. 5B). However, the numbers of positive
cells were significantly reduced to almost undetectable levels
(
1% positive cells; only slightly above the autofluorescent back-
ground attributable to the drug itself) in 17-AAG-treated cells,
irrespective of P coexpression (Fig. 5B). In contrast, the percent-
age of EGFP-P-positive cells was not significantly affected by 17-
AAG treatment, and only a modest effect was observed on the
fluorescence of EGFP-ADAR1, which was used as an irrelevant
control (Fig. 5B). Thus, 17-AAG treatment reduced the expres-
sion of the EGFP-L protein, but not that of other EGFP-tagged
proteins, indicating the effect was specific to the L-protein do-
main.
To determine whether reduced L expression in 17-AAG-
treated cells was the result of protein destabilization caused by loss
of HSP90 chaperone function, we pulse-labeled transfected cells
with [35S]methionine. Subsequently, the accumulation of GFP-
tagged polypeptides was analyzed by SDS-PAGE and autoradiog-
raphy following GFP-Trap IP, either before or after a chase period
with an excess of cold methionine (Fig. 5C). Inhibition of HSP90
chaperone function by 17-AAG had little effect on the quantity of
EGFP-L, EGFP-P, or (as a further control) EGFP-ADAR1 synthe-
sized during the pulse period (Fig. 5C; compare the and – sam-
ples for t	 0). However, while both EGFP-P andADAR1 proteins
showed a slight increase in degradation at 2 h postchase in re-
sponse to 17-AAG treatment, EGFP-L was undetectable in 17-
AAG-treated cells (Fig. 5C, compare the and – samples for t	
2). As expected, EGFP-L was also the least stable protein in the
absence of 17-AAG. Although its stability was increased by coex-
pression of EGFP-P, the presence of EGFP-P was not sufficient to
prevent the accelerated degradation of EGFP-L following treat-
ment with 17-AAG. Thus, blocking HSP90 chaperone function
directly destabilizes L protein, independently of P. Overall, we
concluded that HSP90 is a positive viral factor in the biology of
HRSV, being essential for viral gene expression by promoting the
stability of the viral RNA polymerase.
Role ofHSP70 in the replicationofHRSV. Several other chap-
erones were identified as potential interaction partners of L-EGFP
and/or P-EGFP in the context of the replicon, including the chap-
erone HSP70 (with high significance but a lower binding ratio
than HSP90) and cochaperones: STIP1 and DnaJ (Hsp40) ho-
molog, subfamily A, member 2 (DNJA2). There are no inhibitors
FIG 4 HSP90 inhibition reduces HRSV replication in the context of theminireplicon. (A) Luciferase activity fromBSRT7 cells transfected with the complete (
L) or incomplete ( L) minireplicon system incubated in the presence and absence of 17-AAG was analyzed. Results are expressed as the percentage of relative
light units (RLU) produced in the absence of drug and aremeans standard deviations of triplicate samples. (B) Luciferase protein abundance was assessed and
compared for BSRT7 cells transfected with the minireplicon system () or mock transfected () and either treated () or not treated () with 17-AAG. The
abundance of the viral proteins N, P, and M2-1 were also compared and remained unaffected by the presence of 17-AAG. (C) The abundance of the luciferase
mRNA from the minireplicon was compared by qRT-PCR at 24 h p.i. with (black bar) or without (gray bar) the treatment of 0.5 M 17-AAG added at 4 h
posttransfection. The data were normalized to the control gene GAPDH and are shown as the fold change for each mRNA between 17-AAG-treated transfected
cells and mock-treated cells.
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for the cochaperones STIP1 andDnaJ. Therefore, a small interfer-
ing RNA (siRNA) approachwas used to ablate themRNAs encod-
ing these proteins to investigate whether they had a potential role
in the virus life cycle. While both proteins were ablated/decreased
in abundance by the siRNA approach, the data indicated that this
has no apparent affect on virus biology (data not shown).
HSP70 was previously identified as interacting with the L- and
P-proteins coexpressed andpurified from insect cells (11) and also
with the P-protein alone (12). Using the minireplicon system in
BSRT7 cells, we investigated whether four inhibitors of HSP70
chaperone function (PIF, VER, MKT-077, and YM-1) had an ef-
fect on viral gene expression. The data indicated that luciferase
FIG 5 (A) Indirect immunofluorescence confocal microscopy, showing the localization of HSP90 with L-EGFP in cells in either the presence or absence of 0.5
M17-AAG, which was added at 4 h posttransfection. L-EGFP in untreated cells showed punctate staining. HSP90 was labeled in red, and L-EGFP was detected
as green areas. Colocalization was determined by the yellow signal from the merged image. No L-EGFP protein was visualized in minireplicon-expressing cells
treated with 17-AAG. (B) Flow cytometry analysis showing that HSP90 inhibition reduces the percentage of L-GFP-positive cells. BSRT7 cells were transfected
with the following plasmids: L-EGFP (L), L-EGFP plus P (LP), P-EGFP (P), ADAR1-EGFP (ADAR1), or L () and cultured in the presence or absence of 1M
17-AAG for 18 h prior to harvesting. Themean EGFP fluorescence from 20,000 cells was measured by flow cytometry, and the percentage of EGFP-positive cells
was calculated following gating of EGFP-negative cells (). Error bars represent the standard deviations from biological triplicate samples. ***, P
 0.0001 by
unpaired two-tailed t test. (C). Pulse-chase analysis of the minireplicon system to test whether HSP90 inhibition destabilizes L-EGFP. BSRT7 cells were
transfected with the indicated plasmids: L-EGFP, L-EGFP plus P-EGFP, or ADAR1-EGFP. Nontreated and 17-AAG-treated cells were pulse-labeled 24 h
posttransfection with [35S]methionine for 30 min and either harvested immediately (t	 0) or chased with medium containing an excess of cold methionine for
2 h at 37°C (t 	 2). EGFP-tagged proteins were isolated from the cell lysates by using EGFP-Trap beads, and proteins were analyzed by SDS-PAGE and
autoradiography.HSP90 inhibition destabilizes L-EGFP, as shownby the absence of L-EGFP alone or L-EGFP andP in the presence of 1M17-AAG.The species
corresponding to L-EGFP, P-EGFP, and ADAR1-EGFP are indicated as L-GFP, P-GFP, and GFP-ADAR, respectively.
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activity decreased in a dose-dependent manner with increasing
concentrations of PIF and VER (Fig. 6A). However, when cell
viability was assessed by measuring intracellular ATP levels, both
drugs were clearly toxic at 50Mand above. For PIF, there was no
evidence of selective inhibition of HRSV gene expression, while
for VER, virus gene expression was around 10-fold more sensitive
to the inhibitor than cellular ATP content (Fig. 6A). The actions of
MKT-077 and YM-1 were also evaluated in this system. However,
with both of these inhibitors there was no significant alteration in
the amount of luciferase compared to the untreated controls (Fig.
6A). The data indicated that treated cells expressing the mini-
replicon VER had the greatest effect on its ability to produce
luciferase.
The actions of these inhibitors were also evaluated in HRSV-
FIG 6 HSP70 inhibitors reduceHRSV gene expression. (A) Luciferase activity was analyzed fromBSRT7 cells transfected with the complete ( L) or incomplete
( L) minireplicon system and incubated in the presence and absence of PIF, VER, MKT-077, or YM-1. Results (black lines) are expressed as the percentage of
RLU produced in the absence of drug. Cell viability was assessed bymeasuring intracellular ATP levels (gray lines). All data are the means standard deviations
of triplicate samples. (B) Inhibition of HSP70 by either PIF, VER, MKT-077, or YM-01 resulted in a decrease in an abundance of HRSV proteins at higher
concentrations. VER was shown to be the most effective inhibitor in the context of the replicon system and wild-type infection.
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infected A549 cells by using immunoblotting to compare the level
of viral proteins between untreated and treated, infected cells. No
viral polypeptides were detected in mock-infected cells as ex-
pected, while cellular GAPDH levels remained constant across the
drug concentrations tested, suggesting nomajor toxicity effects in
this cell type when mock infected (Fig. 6B). For PIF, only the
highest concentration of drug tested partially decreased the abun-
dance of viral proteins, and GAPDH abundance remained un-
changed. VER caused a dose-dependent decrease in viral protein
accumulation compared to the untreated or vehicle control
(DMSO) at 5 M and above, but GAPDH abundance also de-
creased in infected cells treated with50 M VER (Fig. 6B). For
MKT-077 and YM-1, the abundance of viral proteins began to
decrease when the concentrations of these drugs were greater than
5 M (Fig. 6B). Thus, inhibition of HSP70 had a deleterious con-
sequence for virus protein expression, and treatment with VER
appeared to be the most effective. However, because of the poten-
tial toxicity of the drugs in cells, we transferred our efforts to
analyzing themore effective VER inhibitor in an in vitro system to
avoid this potential complication.
HSP70 affects HRSV mRNA transcription but not HRSV
RNA polymerization. Whereas published data regarding HSP90
indicate that it has a role in polymerase stability, the data available
regarding HSP70 indicate that it has a more direct role in HRSV
polymerase activity. Previously, Brown et al. showed that follow-
ing HRSV infection, a proportion of HSP70 relocalized to lipid
raft-associated, cytoplasmic inclusions that are believed to be vi-
ral transcription/replication factories (13). Furthermore, it was
shown that an antibody against HSP70 inhibited lipid raft-associ-
ated HRSV polymerase activity (13). More recent studies have
shown that HSP70 copurifies with heterologously expressed
HRSV L/P complexes (11). These findings suggest that HSP70
binds to the HRSV L/P complex and affects polymerase activity.
This is consistent with the EGFP-Trap results (see Tables S1 and
S2 in the supplemental material), although these may also reflect
interactionwith RNPs. To investigate this possibility, the effects of
VER, the inhibitor that had the greatest effect on virus biology in
the context of the minireplicon and wild-type-infected cells, were
examined in two different HRSV polymerase assays. First, we ex-
amined HRSV polymerase activity using an in vitro cell extract
assay (26). HRSV-infected HEp2 cells were gently disrupted and
lysates were incubated in a buffer containing actinomycin D (to
inhibit cellular polymerases) and [-32P]NTP. The radiolabeled
RNA produced was analyzed by denaturing polyacrylamide gel
electrophoresis tomeasure the sumofmultiple different polymer-
ase functions on an intact nucleocapsid template, in a similar
manner to that used by Brown and coworkers (13). Analysis of the
RNA produced in this assay showed that in the absence of VER, a
number of different RNA transcripts were generated in reaction
mixtures containing extract from HRSV-infected cells but not
mock-infected cells (Fig. 7A, compare lanes 1 and 2). This con-
firmed that the HRSV polymerase was active and that the signal
was not contaminated with RNA generated from cellular poly-
merases. Addition of 0.5 M VER led to a slight increase in the
abundance of labeled RNA, but further increases led to a signifi-
cant reduction (Fig. 7A, lanes 2 to 6, and C). These findings indi-
cated that HSP70 is required for, or augments, HRSV polymerase
activity on an intact nucleocapsid template.
Next, we analyzedHRSVpolymerase activity in aminimalist in
vitro RNA synthesis assay, as described previously (11). This assay
utilized recombinant HRSV L- and P-proteins, purified as a com-
plex from insect cells. HSP70 consistently copurifies with L/P un-
der the purification conditions used, in approximately an
equimolar amount with L, and is not completely removed even
under highly stringent washing conditions (11, 35; unpublished
data). Thus, it is possible that HSP70 contributes to the RNA
synthesis activity of the L/P complex. Purified L/P/HSP70 com-
plexes were incubated with a naked RNA oligonucleotide, con-
taining nucleotides 1 to 25 of the trailer-complement (trc)
promoter sequence, in buffer containing NTPs, including [-
32P]GTP. The RNA products were analyzed by denaturing gel
electrophoresis. In the absence ofVER,WTL/P/HSP70 complexes
yielded a series of bands representing products of de novo RNA
synthesis from the promoter andRNA generated by back-priming
and 3= extension of the input template (Fig. 7B, lane 4) (for char-
acterization of the different products, see reference 11). These
bands could not be detected if WT L/P/HSP70 was omitted or
replaced with a mutant version of the complex containing an
amino acid substitution in the polymerization domain of L. In
contrast to what was observed in the HEp2 cell extract assay, in-
clusion of VER in the reaction mixtures had no detectable effect
on RNA synthesis (Fig. 7B, lanes 4 to 8, andD). This result showed
that HSP70 activity does not affect the HRSV polymerization ac-
tivity of the L/P complex per se. Together, these findings indicate
that HSP70 affects HRSV polymerase activity in the context of a
complete nucleocapsid but not on a short, naked RNA template.
DISCUSSION
In this study, the cellular interactomes of the HRSV L- and P-pro-
teins were investigated. IP, coupled with quantitative proteomic
analysis, indicated that HSP90 and several other chaperone pro-
teins involved in the posttranslational folding of cellular proteins
interacted with the L- and P-proteins. The ratio of N- and P-pro-
teins is suggestive that RNPs were also isolated. Other potential
cellular interacting proteins included the identification of thema-
jor vault protein (MVP), identified with the P-protein (see Table
S2 in the supplemental material). MVP constitutes themain com-
ponent of cytoplasmic ribonucleoprotein particles and is possibly
a generic antiviral factor (36). Several other groups of proteins
were identified, including translation factors, cytoskeletal compo-
nents, hnRNPs, and splicing factors. However, extensive analyses
of “bead proteomes” have suggested that these proteins may be
common contaminants in IPs, unless they have a high binding
ratio between the bait and control (29, 30). However, some of
these interactions may be functionally significant, as demon-
strated for the cytoskeleton proteins actin and profilin, which play
important roles in HRSV RNA synthesis (37–39).
Interactors were identified by using GFP-Trap resin to selec-
tively precipitate EGFP-tagged versions of the HRSV L- and P-
proteins, which maintain biological activity in the context of a
minireplicon system (17). Insertion of the EGFP open reading
frame into either polypeptide reduced transcriptional activity in
the minireplicon system compared to the native HRSV L- or P-
proteins, as previously reported (17). This diminution of tran-
scription activity or altered phenotype is commonly found for the
insertion of additional ORFs in other RdRps and can depend on
the location of the insertion site in the RdRp (40–42). Thus, one
concern is that cellular proteins which form interactions with the
L- and/or P-protein may not do so if the function of the viral
protein is attenuated or the insertion of the EGFP disrupts a bind-
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ing site; consequently, these proteins will not be identified in an
interactome screen. Nevertheless, the use of tagged viral proteins
that still maintained biological activity in the cell was advanta-
geous in comparison to similar systems in which biological
activity was not or could not be established. Furthermore, this
approach permitted the isolation of L-protein-containing
complexes, as no antibody to the HRSV L-protein (with which to
perform IPs on the native protein) is publicly available.
Consistent with previously published data from investigations
of the role of HSP90 in HRSV biology (14, 15), inhibiting the
protein chaperone function ofHSP90 by using the small-molecule
inhibitor 17-AAG resulted in a decrease in viral mRNA and pro-
tein levels. In the context of the HRSV minireplicon system, 17-
AAG treatment led to the ablation of reporter gene expression but
not a decrease in the abundance of the proteins expressed from the
support plasmids, indicating a striking effect on virus transcrip-
tion and/or replication (Fig. 4B). Use of the replicon system
(where synthesis of the viral proteins is dependent on T7 tran-
scription of mRNAs rather than the HRSV RNA polymerase) al-
lowed themechanism of this global effect on viral gene expression
to be dissected; 17-AAG treatment specifically reduced the accu-
mulation of the viral L-protein. Expression of EGFP-L in isolation
allowed us to perform kinetic analyses of protein expression and
stability in the absence and presence of the P-protein cofactor
FIG 7 HSP70 affects HRSV transcription, but not RNApolymerization. (A) Addition of VER inhibits RSVmRNA synthesis in a cell extract in vitro. Lane 1, RNA
from a reaction mixture containing mock-infected cell extract; lanes 2 to 6, RNA from a reaction mixture containing HRSV-infected cell extracts, with
[-32P]GTP as the labeled NTP and various concentrations of VER included in the reaction mixture, as indicated. The asterisk indicates the RNA band that was
quantified to generate the graph in panel C. (B) Addition of VER did not inhibit HRSV RNA synthesis in an assay utilizing purified polymerase complexes. Lane
2, a negative control in which the L/P/HSP70 complex was omitted from the reaction mixture; lane 3, a negative control in which reaction mixtures were
incubated with an L/P/HSP70 complex containing the N812A substitution at the catalytic site of the L-protein; lanes 3 to 8 show RNA generated from WT
L/P/HSP70 complexes in the presence of various concentrations of VER. Lane 1 contains a size marker representing the expected products of de novo RNA
synthesis from position 1 of the trc promoter. The bands representing RNA generated by de novo synthesis from the promoter, or 3= extension of the input
template, are indicated. (C) Bar chart showing levels of RNA synthesis in the HEp2 cell extract assay, based on quantification of the bandmarked with an asterisk
in panel A. The data show themeans and ranges of two independent experiments. (D) Bar chart showing levels of RNA synthesis in theminimalist RNA synthesis
assay involving purified L/P/HSP70 complexes, based on quantification of the 21-nucleotide band marked with an asterisk in panel B. The data show the means
and standard errors of the means from two or three independent experiments. In panels C and D, the data from each experiment were normalized to the level of
labeled RNA produced in the absence of VER, which was set to a value of 1.
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(Fig. 5C). The simplest explanation consistentwith our data is that
HSP90 directly interacts with the L-protein to perform an essen-
tial chaperone function during its folding that is essential for its
stability. This is also consistent with previous studies: Geller et al.
postulated that the ablation of HSP90 activity had a detrimental
effect on HRSV L-protein stability (15), and a similar hypothesis
was proposed by Connor et al. based on their analysis of the effect
of HSP90 inhibitors on the stability of the related VSV L-protein
(16). Using metabolic labeling in conjunction with IP (based on a
polyclonal RSV antibody), Geller et al. (15) observed specific deg-
radation of a single250-kDa viral protein, corresponding to the
molecular mass of the HRSV L-protein in virus-infected cells.
However, as discussed (15), this could not be positively identified
due to the lack of specific sera. Using a tagged EGFP-L fusion
protein which could be specifically identified through the EGFP
moiety, we were able to confirm the effect of HSP90 activity on
L-protein (in the presence or absence of P-protein) by using sev-
eral different approaches.
Apart from HSP90, other chaperones that potentially inter-
acted with the L- and P-proteins were HSP70, STIP1, and
DNAJA2. In the absence of available inhibitors, siRNAwas used to
ablate STIP1 and DNAJA2 in HRSV infected cells, but with no
apparent effect on virus biology (data not shown). Previous stud-
ies indicated that HSP70 might play a direct role in HRSV RNA
synthesis and/or virus assembly (13). The data presented here po-
tentially supported these findings. PIF and VER affected both rep-
licon activity and protein synthesis in HRSV-infected cells, sug-
gesting a positive role for HSP70 in replication of viral RNA,
whereas MKT-077 and YM-1 appeared to negatively affect the
abundance of viral proteins but not the synthesis of viral RNA.
This illustrates the potentially difficulty of workingwith inhibitors
and the necessity to use different experimental approaches to as-
sess their impact on virus biology.
To investigate the effect of HSP70 in further detail, we em-
ployed an in vitro system. This assay, involving HRSV-infected
HEp2 cell extract, showed that addition of the HSP70 inhibitor
VER to the reaction mixture led to a 5-fold decrease in the level of
HRSV RNA synthesis, indicating that HSP70 plays a positive role
in HRSV RNA synthesis (Fig. 7A and C). In contrast to these
findings, VER had no detectable effect in an experiment utilizing a
minimalist assay, involving purified recombinant L- and P-pro-
teins in complex with HSP70 (Fig. 7B and D).
A major difference between the two assays lies in the nature
of the template. In the HEp2 cell-based extract assay, the tem-
plate was an intact nucleocapsid, whereas in the minimalist
assay (complex purified from insect cells), it was a naked RNA
oligonucleotide. Thus, a possible explanation for why VER in-
hibited RNA synthesis in the HEp2 cell extract assay, but not in
the minimalist assay, is that HSP70 might help the polymerase
remodel the nucleocapsid to allow RNA synthesis to occur ef-
ficiently. This hypothesis is consistent with data obtained for
other nonsegmented negative-strand RNA viruses. HSP70 has
been shown to associate with the N-protein of the paramyxo-
virus measles virus and the rhabdovirus rabies virus and to
positively affect RNA synthesis in both cases (43–45). Thus,
HSP70 might be involved in nucleocapsid remodeling for a
number of nonsegmented negative-strand RNA viruses, but it
may accomplish this role by binding different proteins within
the nucleocapsid complex, depending on the virus. Surpris-
ingly, when a lower concentration of VER (0.5 M) was in-
cluded in the HEp2 cell extract assay mixture, there was a slight
increase in RNA synthesis (Fig. 7A and C). This is also similar
to results obtained with an HSP70 antibody, with which it was
shown that a low concentration of antibody led to a slight
increase in RNA synthesis, but higher concentrations inhibited
synthesis (13). This intriguing finding suggests that the effect of
HSP70 depends on its active concentration. It is possible that
relatively lower HSP70 activity promotes nucleocapsid restruc-
turing and RNA synthesis, whereas a relatively higher HSP70
activity renders the nucleocapsid inactive.
We postulate that HSP90 and other chaperone proteins,
such as HSP70, may also be required for maintaining the cor-
rect folding, and therefore functionality, of viral proteins in the
RNP complex. In this system, EGFP-L protein was ablated in
the presence of 17-AAG, and heat shock proteins in general
have been found to be essential for polymerase stability/activity
and/or viral replication in other negative-strand RNA viruses,
including VSV and other paramyxoviruses (16), La Crosse bu-
nyavirus (16), rabies virus (44), Ebolavirus (46), and influenza
virus (47–49).
Although HRSV replication is inhibited in cell culture by a
range of HSP90 inhibitors (14, 15), continuous passage of the
virus in the presence of the drugs did not select for resistant viruses
(15), suggesting that inhibition of chaperone proteins could offer
a generic antiviral therapeutic approach (23). The general ap-
proach of using quantitative proteomics to identify cellular pro-
teins that are critical for virus biologymay open upnew avenues of
therapeutic intervention. This illustrates the versatility of target-
ing cellular proteins, rather than viral proteins, as illustrated by
work targeting EBOV biology (21, 46). Transiently targeting the
function of host cell proteins which are crucial to virus biology
offers an exciting new therapeutic avenue with the potential to
solve the problem of resistance, as proviral cellular proteins are
evolutionarily static on the time scale of lytic virus replication, as
well as genetically separate from the genome, which would benefit
from resistance. Many of these small-molecule inhibitors are pre-
existing clinically relevant therapeutics and could be potentially
safely repurposed as part of an antiviral strategy.
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